Latest Pharma and Biotech News
Biotechnology
30 December 2024 Antibody-drug conjugates (ADCs) combine monoclonal antibody (MAb) specificity with cytotoxic drug potency via a linker, delivering targeted cancer therapy. ADCs concentrate treatment at tumor sites, enhancing efficacy while minimizing harm to healthy tissues.
Today's issue
Refine Search
Biotechnology
Among significant news in a holiday spattered week, Dutch biotech argenx gained another approval in Japan for its Vyvdura (efgartigimod alfa and hyaluronidase-qvf), this time for adult patients with demyelinating polyneuropathy (CIDP). Axsome Therapeutics released mixed results from the completed Phase III program for its Alzheimer’s agitation candidate AXS-05 (dextromethorphan-bupropion and aminoketone). Also, Sangamo plunged on the news that Pfizer had unexpectedly pulled out of their deal on the development of hemophilia A candidate giroctocogene fitelparvovec (giro-vec). 5 January 2025
Biotechnology
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK pharma major GSK that targets interleukin-5 (IL-5). 3 January 2025
Biotechnology
In Beijing, a series B round for PrimeGene Science and Technology has raised over 300 million renminbi ($46 million), with money from investors including Beijing Pharmaceutical and Health Industry Investment Fund. 3 January 2025
Biotechnology
WuXi Biologics has signed a deal with Sino Biopharm to develop a first-in-class monoclonal antibody targeting an undisclosed indication. 3 January 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceuticals has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) for Lunsumio (mosunetuzumab) for intravenous infusion 1mg and 30mg for the treatment of patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received two or more prior standard therapies. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics represent, fundamentally transforming how cancer is treated. 3 January 2025
Pharmaceutical
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that its experimental depression treatment failed in the first of three studies planned by the biotech company. 3 January 2025
Biotechnology
US biotech Capricor Therapeutics today announced the completion of the submission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking full approval for deramiocel, an investigational cell therapy, to treat patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy 2 January 2025
Biotechnology
China’s Innovent Biologics today announced a collaboration and exclusive license agreement with Swiss pharma giant Roche to advance the development of IBI3009, a novel DLL3-targeted antibody drug conjugate (ADC) candidate. 2 January 2025
Pharmaceutical
Hutchmed has announced agreements to divest its 45% equity stake in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for $608 million in cash. The buyers are GP Health Service Capital and Shanghai Pharmaceuticals. 2 January 2025
Pharmaceutical
Kazia Therapeutics, an oncology-focused Australian drug developer, has been advised by the US Food and Drug Administration (FDA) that accelerated approval for its brain cancer drug, paxalisib, is unlikely. 2 January 2025
Biotechnology
California-based IDEAYA Biosciences has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo-I-payload antibody-drug conjugate (ADC) program with China’s Jiangsu Hengrui Pharmaceuticals. 2 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Biotechnology
Austrian arenaviral technology firm HOOKIPA Pharma and Poolbeg Pharma have entered into non-binding discussions for an all-share acquisition by HOOKIPA of London-listed Poolbeg to create a strong clinical-stage biopharmaceutical company. 2 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defactinib. 2 January 2025
Pharmaceutical
The new $2,000 cap on out-of-pocket costs for prescription drugs went into effect as of January 1, 2025, the US Department of Health and Human Services (HHS) Secretary Xavier Becerra has announced. 2 January 2025
Biotechnology
Pfizer has unexpectedly decided to end its collaboration with Sangamo Therapeutics on giroctocogene fitelparvovec (giro-vec). 2 January 2025
Pharmaceutical
The market for artificial intelligence (AI) in cancer care is projected to grow from $2.2 billion in 2024 to $6.3 billion by 2029, reflecting a growth rate of 23.1%, according to a recent study by BCC Research. 31 December 2024
All news
Biotechnology
Among significant news in a holiday spattered week, Dutch biotech argenx gained another approval in Japan for its Vyvdura (efgartigimod alfa and hyaluronidase-qvf), this time for adult patients with demyelinating polyneuropathy (CIDP). Axsome Therapeutics released mixed results from the completed Phase III program for its Alzheimer’s agitation candidate AXS-05 (dextromethorphan-bupropion and aminoketone). Also, Sangamo plunged on the news that Pfizer had unexpectedly pulled out of their deal on the development of hemophilia A candidate giroctocogene fitelparvovec (giro-vec). 5 January 2025
Biotechnology
China’s National Medical Products Administration (NMPA) has approved Nucala (mepolizumab), a monoclonal antibody from UK pharma major GSK that targets interleukin-5 (IL-5). 3 January 2025
Biotechnology
In Beijing, a series B round for PrimeGene Science and Technology has raised over 300 million renminbi ($46 million), with money from investors including Beijing Pharmaceutical and Health Industry Investment Fund. 3 January 2025
Biotechnology
WuXi Biologics has signed a deal with Sino Biopharm to develop a first-in-class monoclonal antibody targeting an undisclosed indication. 3 January 2025
Pharmaceutical
Full mergers and acquisitions in the pharmaceutical and biotechnology in 2024 fluctuated throughout the year with hardly any in some months and a significant number in other. But one thing was clear – buyers were shying away from big bets on commercially ready medicines in favor of earlier stage drug developers. 3 January 2025
Biotechnology
Japanese drugmaker Chugai Pharmaceuticals has obtained regulatory approval from the Ministry of Health, Labor and Welfare (MHLW) for Lunsumio (mosunetuzumab) for intravenous infusion 1mg and 30mg for the treatment of patients with relapsed or refractory (R/R) follicular lymphoma (FL) who have received two or more prior standard therapies. 3 January 2025
Pharmaceutical
Regeneron Pharmaceuticals has acquired UK-based biotech Oxular, enhancing its gene therapy development program with the firm’s specialized ocular delivery tech. 3 January 2025
Pharmaceutical
One of the most promising areas of medical innovation in the next five years is immuno-oncology (I-O)/cancer therapeutics represent, fundamentally transforming how cancer is treated. 3 January 2025
Pharmaceutical
Massachusetts, USA-based based brain disease biotech Neumora Therapeutics shares tumbled 81.4% to 1.97 after it revealed that its experimental depression treatment failed in the first of three studies planned by the biotech company. 3 January 2025
Biotechnology
US biotech Capricor Therapeutics today announced the completion of the submission of its Biologics License Application (BLA) to the US Food and Drug Administration (FDA) seeking full approval for deramiocel, an investigational cell therapy, to treat patients diagnosed with Duchenne muscular dystrophy (DMD) cardiomyopathy 2 January 2025
Biotechnology
China’s Innovent Biologics today announced a collaboration and exclusive license agreement with Swiss pharma giant Roche to advance the development of IBI3009, a novel DLL3-targeted antibody drug conjugate (ADC) candidate. 2 January 2025
Pharmaceutical
Hutchmed has announced agreements to divest its 45% equity stake in Shanghai Hutchison Pharmaceuticals Limited (SHPL) for $608 million in cash. The buyers are GP Health Service Capital and Shanghai Pharmaceuticals. 2 January 2025
Pharmaceutical
Kazia Therapeutics, an oncology-focused Australian drug developer, has been advised by the US Food and Drug Administration (FDA) that accelerated approval for its brain cancer drug, paxalisib, is unlikely. 2 January 2025
Biotechnology
California-based IDEAYA Biosciences has entered into an exclusive license agreement for SHR-4849, a novel DLL3-targeting Topo-I-payload antibody-drug conjugate (ADC) program with China’s Jiangsu Hengrui Pharmaceuticals. 2 January 2025
Pharmaceutical
The type 1 diabetes (T1D) market across the seven major markets (7MM: USA, France, Germany, Italy, Spain, the UK, and Japan) is set to grow at a compound annual growth rate (CAGR) of 13.3% from $2.2 billion in 2023 to $9.9 billion in 2033. 2 January 2025
Biotechnology
Austrian arenaviral technology firm HOOKIPA Pharma and Poolbeg Pharma have entered into non-binding discussions for an all-share acquisition by HOOKIPA of London-listed Poolbeg to create a strong clinical-stage biopharmaceutical company. 2 January 2025
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) under the accelerated approval pathway for avutometinib, an oral RAF/MEK clamp, in combination with defactinib. 2 January 2025
Pharmaceutical
The new $2,000 cap on out-of-pocket costs for prescription drugs went into effect as of January 1, 2025, the US Department of Health and Human Services (HHS) Secretary Xavier Becerra has announced. 2 January 2025
Biotechnology
Pfizer has unexpectedly decided to end its collaboration with Sangamo Therapeutics on giroctocogene fitelparvovec (giro-vec). 2 January 2025
Pharmaceutical
The market for artificial intelligence (AI) in cancer care is projected to grow from $2.2 billion in 2024 to $6.3 billion by 2029, reflecting a growth rate of 23.1%, according to a recent study by BCC Research. 31 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze